| | 110267-81-7 Basic information More.. |
| Product Name: | Amrubicin | | Synonyms: | (7S,9S)-9-Acetyl-9-amino-7-[(2-deoxy--D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione;(7S)-9β-Amino-9-acetyl-7β-[(2-deoxy-β-D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxynaphthacene-5,12-dione;(7S,9S)-9-Acetyl-9-amino-7-(2-deoxy-β-D-erythro-pentopyranosyloxy)-6,11-dihydroxy-5,7,8,9,10,12-hexahydro-5,12-naphthacenedione;(7S,9S)-9-Amino-9-acetyl-7-[(2-deoxy-β-D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxynaphthacene-5,12-dione;Amurubicin;5,12-Naphthacenedione,9-acetyl-9-aMino-7-(2-deoxy-b-D-erythro-pentopyranosyl)oxy-7,8,9,10-tetrahydro-6,11-dihydroxy-,(7S,9S)-;CS-1168;5,12-Naphthacenedione, 9-acetyl-9-amino-7-[(2-deoxy-β-D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxy-, (7S,9S)- | | CAS: | 110267-81-7 | | MF: | C25H25NO9 | | MW: | 483.47 | | EINECS: | | | Mol File: | 110267-81-7.mol |  |
Use
Amrubicin is an active agent for the treatment of small-cell lung cancer (SCLC). It is a type of anthracycline analog. Anthracycline derivatives such as doxorubicin (DXR), daunorubicin (DNR) and epirubicin have been widely used for a variety of carcinomas in the clinical context. Amrubicin is structurally distinguishable from other anthracyclines by the amino group at the 9-position and its unique sugar moiety. In April 2002, Amrubicin was approved in Japan for the treatment of non-small cell lung cancer and small cell lung cancer.
- Amrubicin
-
- US $15.00-10.00 / KG
- 2021-07-02
- CAS:110267-81-7
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
- AMRUBICIN
-
- US $1.00 / g
- 2019-12-26
- CAS:110267-81-7
- Min. Order: 1g
- Purity: ≥98%
- Supply Ability: g/kg/Ton
|
|
110267-81-7
Recommend Suppliers |
|